News & Events
4 November 2009 - Merck and Schering-Plough Complete Merger
3 November 2009 - Merck and Schering-Plough Complete Merger. Merck & Co., Inc. announced completion of its merger with Schering-Plough Corporation as of 3 November 2009. Click here for the full press release from Merck & Co., Inc.
7 September 2009 - Meda Pharmaceuticals, Inc. has expanded rights for azelastine and fluticasone combination. Cliick here for the full press release from Meda Pharmaceuticals, Inc.
2 September 2009 - Meda Pharmaceuticals, Inc. receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine. Click here for the full press release from Meda Pharmaceuticals, Inc.
4 August 2009 - Par Pharmaceutical reports successful launch of NasCobal, Vitamin B12 nasal spray. Click here for the full press release from Par Pharmaceutical.
21 July 2009 - Proveris Scientific Corporation
21 July 2009 - Valois and Pfeiffer Adopt Proveris's Complete Solution - Proveris Scientific Corporation announced today the adoption by Valois Pharma and Ing. Erich Pfeiffer GmbH - leading pump and valve manufacturers in the pharmaceutical industry - of its complete solution for spray analysis and release testing. Proveris's complete solution incorporates an instrument service plan, software licensing, and software support and maintenance.
"Together with Proveris's instruments, the complete solution provides the scalability we need to perform robust, high through-put product testing," said Salim Haffar, President of Valois Pharma.
"We value the relationship with Valois Pharma and Pfeiffer," said Zach Pitluk, Vice President of Commercialization at Proveris Scientific Corporation, "because it allows us to support many current and future OINDP (Orally Inhaled and Nasal Drug Products) projects. Proveris respects the technology and innovativeness of Valois Pharma and Pfeiffer in the OINDP marketplace and looks forward to providing them with complete solutions for spray characterization and release testing."
About Proveris Scientific Corporation
Proveris Scientific streamlines complex development and release testing processes of pharmaceutical spray products by providing complete solutions that reduce overall lab testing time by at least 100 fold when compared to manual analysis. Proveris's complete solutions incorporate the cGMP-enabled Viota® informatics platform to manage and analyze data; the pioneering SprayVIEW® instrument for robust, FDA accepted spray pattern and plume geometry analysis; and the robotic Indizo® instrument for walk-away, highly reproducible shot weight and content uniformity results. Proveris has deployed its complete solutions globally at over 60 pharmaceutical development and manufacturing sites. Proveris's complete solutions are used by the FDA and the pharmaceutical industry to set testing standards and generate robust data for their applications (please see our website www.proverisscientific.com for a list of recent publications). Proveris is certified to ISO9001:2008 by TUV Rheinland of North America and has over 15 US and internationally issued patents on it technology.
Company Contact: Zach Pitluk, Vice President of Commercialization at Proveris Scientific Corporation, (508) 460-8822 Ext. 7634, zpitluk@proverisscientific.com.
Media Contact: Lynn Blenkhorn, Feinstein Kean Healthcare, (508) 851-0930, lynn.blenkhorn@fkhealth.com.
About Pfeiffer and Valois Pharma
Valois Pharma, a division of Valois S.A.S., and Ing. Erich Pfeiffer GmbH are world leaders in nasal and pulmonary drug delivery technologies with a broad range of innovative drug delivery devices, technologies and services. Ing. Erich Pfeiffer GmbH and Valois S.A.S. are wholly owned subsidiaries of AptarGroup, Inc., a publicly traded company listed on the New York Stock Exchange (NYSE: ATR).
For further information visit www.pfeiffer-group.com or www.valoispharma.com.
8 May 2009 - Archimedes Pharma Limited announces ground breaking Phase III data showing Nasalfent to be superior to the standard of care from breakthrough cancer pain. Click here for the full press release from Archimedes Pharma Limited
9 March 2009 - Schering-Plough Corporation announced that its Board of Directors has unanimously approved a definite merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Click here for the full press release from Schering-Plough Corporation
2 March 2009 - Intranasal Therapeutics, Inc. changes name to Ikano Therapeutics and completes $9 million series B financing. Click here for the full press release from Intranasal Therapeutics, Inc.
26 February 2009 - Archimedes Pharma Limited, announces successful proof-of-concept results on two intranasal development projects. Click here for the full press release from Archimedes Pharma Limited
22 December 2008 - NovaDel Pharma Inc., announces that it has received FDA approval of Zolpimist™ 5 mg and 10 mg oral spray for short-term treatment of insomnia characterized by difficulties with sleep initiation. The active ingredient in the product is the same as the active ingredient in Sanofi Aventis's Ambien® product, the patent for which expired on April 21, 2007. The Zolpimist™ product uses NovaDel's proprietary NovaMist™ oral spray technology. Click here for the full press release from NovaDel Pharma Inc.
17 October 2008 - Meda AB
17 October 2008 - Meda AB, announces FDA approval of Astepro® nasal spray, a new formulation of Astelin for treatment of seasonal allergic rhinitis. The active ingredient in the product is azelastine, the leading antihistamine in the treatment of rhinitis in the U.S. Click here for the full press release from Media AB.
9 October 2008 - Archimedes Pharma Limited, announces positive Phase III results for NasalFent® nasal spray for cancer pain. The fentanyl citrate nasal spray treats breakthrough cancer pain - unpredictable, sudden intense pain that affects the majority of cancer patients. Click here for the full press release from Archimedes Pharma.
Proveris Scientific UK Limited
November 2008, Proveris Scientific Corporation (Proveris) announces the opening of a UK based office. Proveris Scientific UK Limited (Proveris UK), a wholly-owned subsidiary of Proveris Scientific Corporation, will support Proveris’s growing customer base in Europe and Asia. Proveris UK has hired Ivan Prince to manage its service and support operations. Mr. Prince brings to the position his experience as both a scientist and system engineer for Respironics. Proveris welcomes Mr. Prince and invites its customers in Europe and Asia to contact him with service and support questions. Proveris UK is located at 1000 Lakeside, North Harbour, Western Road, Portsmouth PO6 3EZ.